2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-118335S
    Prazobind-d8 1189701-23-2 98%
    Prazobind-d8 (SZL 49-d8) is the deuterium labeled Prazobind (HY-118335). Prazobind, a prazosin analog, is an irreversible α1-adrenoceptor antagonist. Prazobind competes for alpha 1-adrenoceptor binding sites with a similar potency (IC50 of 1 nM) in tissues enriched in both the alpha 1A (hippocampus) and alpha 1B (liver) subtypes. Prazobind partially inhibits the contractions of circular muscles, longitudinal muscles and smooth muscles of the spleen. Prazobind can be used for the study of blood pressure.
    Prazobind-d8
  • HY-132670S
    (R)-(-)-Felodipine-d5 1217744-87-0 98%
    (R)-(-)-Felodipine-d5 is the deuterium labeled (R)-(-)-Felodipine. (R)-(-)-Felodipine is the S enantiomer of Felodipine. Felodipine, a dihydropyridine, is a potent, vasoselective calcium channel antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels. Felodipine, an anti-hypertensive agent, induces autophagy. Felodipine can cross the blood-brain barrier.
    (R)-(-)-Felodipine-d5
  • HY-15025S1
    Sildenafil-d8 951385-68-5 98%
    Sildenafil-d8 is the deuterium labeled Sildenafil. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM.
    Sildenafil-d8
  • HY-17495AS
    Carteolol-d9 hydrochloride 1346602-13-8 98%
    Carteolol-d9 (hydrochloride) is the deuterium labeled Carteolol hydrochloride. Carteolol hydrochloride (OPC-1085 hydrochloride) is a non-selective beta blocker used to treat glaucoma.
    Carteolol-d9 hydrochloride
  • HY-17503S1
    (R)-Metoprolol-d7 1292907-84-6 98%
    (R)-Metoprolol-d7 is the deuterium labeled Metoprolol. Metoprolol (Toprol) is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension[1][2].
    (R)-Metoprolol-d7
  • HY-17503S2
    (S)-Metoprolol-d7 1292906-91-2 98%
    (S)-Metoprolol-d7 is the deuterium labeled Metoprolol. Metoprolol (Toprol) is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension[1][2].
    (S)-Metoprolol-d7
  • HY-B0280S2
    Ranolazine-d3 1054624-77-9 99.49%
    Ranolazine-d3 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP). Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor. Antianginal agent.
    Ranolazine-d3
  • HY-B0431AS
    Phenoxybenzamine-d5 hydrochloride 1329838-45-0 98%
    Phenoxybenzamine-d5 (hydrochloride) is the deuterium labeled Phenoxybenzamine hydrochloride. Phenoxybenzamine hydrochloride is a nonselective, irreversible, orally active α-adrenoceptor antagonist that is commonly used for the research of hypertension, specifically caused by pheochromocytoma. Phenoxybenzamine hydrochloride also shows antitumor activity[1][2][3].
    Phenoxybenzamine-d5 hydrochloride
  • HY-10269
    LY-517717 313489-71-3 98%
    LY-517717 is a potent and orally active FXa inhibitor. LY-517717 shows antithrombotic and anticoagulant activity. LY-517717 has the potential for the research of venous thromboembolism after hip or knee replacement.
    LY-517717
  • HY-10270
    Flovagatran 871576-03-3 98%
    Flovagatran (TGN 255) is a potent and reversible thrombin inhibitor (Ki: 9 nM). Flovagatran can be used in the research of arterial and venous thrombosis.
    Flovagatran
  • HY-10273
    Atecegatran metoxil 433937-93-0 98%
    Atecegatran metoxil is a oral anticoagulant, which inhibits thrombin factor II and is used in thromboembolic disorders. In vivo, Atecegatran metoxil is converted to AR-H067637, a selective and reversible direct thrombin inhibitor.
    Atecegatran metoxil
  • HY-10281
    YM-60828 methanesulfonate 209187-02-0 98%
    YM-60828 methanesulfonate is an orally active, selective and competitive factor Xa inhibitor with a Ki of 1.3 nM and an IC50 of 2.3 nM. YM-60828 methanesulfonate inhibits thrombus formation and platelet aggregation. YM-60828 methanesulfonate can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders.
    YM-60828 methanesulfonate
  • HY-10304
    Orbofiban 163250-90-6 98%
    Orbofiban is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.
    Orbofiban
  • HY-10305
    Xemilofiban 149820-74-6 98%
    Xemilofiban is an orally active glycoprotein IIb/IIIa blocking agent. Xemilofiban inhibits platelet aggregation. Xemilofiban reduces the incidence of thrombosis.
    Xemilofiban
  • HY-10307
    Roxifiban 170902-47-3 98%
    Roxifiban is a platelet glycoprotein (GP) IIb/IIIa receptor inhibitor that can be used in the study of angina.
    Roxifiban
  • HY-10312
    UR-12947 718595-27-8 98%
    UR-12947 is a platelet glycoprotein (GP) IIb-IIIa antagonist. UR-12947 exhibits potent inhibitory activity against platelet aggregation in human platelet-rich plasma, with an IC50 value of 3.5 nM. UR-12947 can be used in the research of arterial thrombotic diseases.
    UR-12947
  • HY-10313
    ZD 2486 185836-64-0 98%
    ZD 2486 is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist. ZD 2486 inhibits platelet aggregation by blocking the binding of fibrinogen to the GP IIb/IIIa receptor on platelets. ZD 2486 can be used for the study of conditions related to unwanted platelet aggregation, such as acute coronary syndrome, unstable angina pectoris, acute myocardial infarction, and complications from cardiovascular interventional procedures[1]
    ZD 2486
  • HY-10314
    Lotrafiban 171049-14-2 98%
    Lotrafiban is an orally-active platelet GPIIb/IIIa blocker for research of coronary and cerebrovascular disease.
    Lotrafiban
  • HY-10315
    Elarofiban 198958-88-2 98%
    Elarofiban (RWJ-53308) is a nonpeptide, orally active antagonist for fibrinogen receptor αIIbβ3 (GPIIb/IIIa), with an IC50 of 0.15 nM. Elarofiban has the potential for platelet mediated thrombotic disorders research.
    Elarofiban
  • HY-10335
    BMS-645737 651744-16-0 98%
    BMS-645737 is an orally active, selective FGF receptor-1 and VEGF receptor-2 inhibitor. BMS-645737 selectively and competitively inhibits both VEGFR-2 and FGFR-1 tyrosine kinases. BMS-645737 has anti-angiogenic activity. BMS-645737 induces lesions in the incisor teeth.
    BMS-645737
Cat. No. Product Name / Synonyms Application Reactivity